Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A Retrospective Analysis

• Main Authors: Yu-Wen Chang (Author), Meng-Yun Tsai (Author), Yu-Ping Chang (Author), Chien-Chang Liao (Author), Yu-Ting Lin (Author), Chien-Hao Lai (Author), Meng-Chih Lin (Author), Kuo-Tung Huang (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background and Objectives Nintedanib, a tyrosine kinase inhibitor, is integral in slowing pulmonary fibrosis progression in chronic fibrotic interstitial lung disease (ILD). However, the occurrence of adverse drug reactions (ADRs) often limits its use, leading to treatment discontinuation,...